Merck
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
In Brief This Week: Becton Dickinson; Delfi Diagnostics; OpGen; GeneDx; Angle
News items for the week of June 3, 2024.
Owkin, MSD Collaborate on Digital Pathology Cancer Diagnostics
Owkin and MSD — known as Merck in the US and Canada — will develop and commercialize microsatellite instability high diagnostics in the EU for four types of cancer.
Agilent Gets FDA Approval of Expanded Use of CDx Assay for Keytruda
The firm said it secured agency approval for its PD-L1 IHC 22C3 PharmDx test to guide treatment of patients with gastric or GEJ adenocarcinoma.
The firm is expanding its lab capabilities and leveraging its test development reputation to form partnerships early in the drug development process.